Ferring eyes Indian degarelix launch late next year
This article was originally published in Scrip
Executive Summary
The Swiss specialty biopharmaceutical company, Ferring Pharmaceuticals, is moving towards the potential launch of its gonadotropin-releasing hormone receptor antagonist, degarelix, on the Indian market for the treatment of prostate cancer.